Wedbush Securities’s BioCardia BCDA Stock Holding History

Wedbush Securities’s Portfolio BCDA Stock Details BCDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,000	Closed	-$6K	–	1202
2024 Q1	$6K	Hold	1,000	–	–	﹤0.01%	1229
2023 Q4	$10K	Hold	1,000	–	–	﹤0.01%	1082
2023 Q3	$6K	Hold	1,000	–	–	﹤0.01%	1054
2023 Q2	$40K	Buy	+1,000	New	+$30.8K	﹤0.01%	1041

Other funds holding BCDA

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Pingora Partners Wilson, Wyoming $171M AUM 60.67% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

GRP

Global Retirement Partners San Rafael, California $6.54B AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wedbush Securities's BCDA Position: Q2 2024 in Review

Wedbush Securities sold out of BioCardia (BCDA) in Q2 2024, closing a stake of 1,000 shares — an estimated $6K sold.

Wedbush Securities first reported a position in BCDA in Q2 2023 and held it in 4 quarters. The position peaked at $40K in Q2 2023. 10 funds tracked by Wall St. Rank hold BCDA as of Q2 2024.

Wedbush Securities reported no remaining BioCardia position as of Q2 2024 after selling out during the quarter.
Wedbush Securities sold 1,000 BioCardia shares in Q2 2024, an estimated $6K.
Wedbush Securities first reported a position in BioCardia in Q2 2023 and held it in 4 quarters.
Wedbush Securities's BioCardia position peaked at $40K in Q2 2023.
10 funds tracked by Wall St. Rank held BioCardia as of Q2 2024.

Based on Wedbush Securities's 13F filing for Q2 2024, filed 7 Aug 2024.